MYMD News and Press, MyMD Pharmaceuticals Inc. From 02/15/24

2024-02-15 08:02:10 ET MyMD Pharmaceuticals Inc (MYMD) announced stock split at a ratio of 1-for-30 on 2024-02-15 ... Full story available on KlickAnalytics.com

2024-02-13 15:30:12 ET More on MyMD Pharmaceuticals Financial information for MyMD Pharmaceuticals Read the full article on Seeking Alpha For further details see: MyMD Pharmaceuticals down after announcing reverse stock split

Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024 MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, ...

BALTIMORE, MD / ACCESSWIRE / December 29, 2023 / A condition that commonly affects elderly populations, sarcopenia results in the gradual loss of strength and physical function and has become an important healthcare issue worldwide in recent years. A sarcopenia diagnosis comes with a greater...

Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharm...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

MyMD Pharmaceuticals Inc. (MYMD) is expected to report for Q1 2024

- Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours - Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects - MyMD was issued Japanese Patent No. 7293561 ...

- Company to share new positive, statistically significant results across Cohort 4 (1050mg) from Phase 2 study of MYMD-1 in sarcopenia, an age-related frailty disorder - MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”),...

- Next-generation and first oral TNF-α inhibitor, which completed Phase 2 study for age-related condition sarcopenia, represents a potentially groundbreaking advance in the treatment of RA and disruption of a $41 billion industry - Acceptance follows statistically significant Pha...